Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from $147 with an Overweight rating on ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc. (NASDAQ ...

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 19, ...

Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.

Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...

In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.14%. Elsewhere, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General ...

Repare Therapeutics shares jumped in premarket trading after the company agreed to sell its polymerase theta ATPase inhibitor to Gilead Sciences for up to $30 million. Shares were 18% higher at $2.57 ...

Keeley Wettan is succeeding Deborah Telman, who stepped down in November for reasons the company didn't explain.

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...